{"ticker": {"uuid": "2a14d988-c858-45ad-88c1-a8f7c00f8ada", "symbol": "NRIX", "name": "Nurix Therapeutics\u00a0Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Nurix Therapeutics, Inc. Stock 12\u2011Month Price Target Raised to $32.87, Implies 42% Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxNZ3VFYVYxMnpUTnZrX08xTlozaGU3cmw1MzZ5cm1mYzlhSjNPbGN0dWZwU2daYmIyLUVGUWRRR25Qemt0d1hLSGpMd1J5a0J4V1VJTUhSQTJHUlQxdl9hM0hNMDBjT2lhN0gyR2hfRVEzbUVHTmhRZWlpLXJEWno0NkFuMmJjb29TQi16UGhZQ3R3U1lXcEVwVXR2YVpJVzB2LUFSb3dQNUI2SGI3Zm9NQ2diR1Izek0xYzZ0NUVYUFo0U3dQODdlbDVIOW0yUllaZDFsTmtUWjQybFdQd1lN?oc=5", "source_name": "TradingView", "published_at": "2026-07-17T04:20:00+00:00", "published_display": "17 Jul 2026 04:20", "sentiment": "positive", "sentiment_pct": 80, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Average Rating of \"Moderate Buy\" by Brokerages", "summary": "Nurix Therapeutics, Inc. (NASDAQ:NRIX) has received an average rating of \"Moderate Buy\" from fourteen brokerages, with an average 12-month price target of $34.08. Several analysts have recently raised their price targets, despite the company missing its latest quarterly earnings ", "url": "https://www.marketbeat.com/instant-alerts/nurix-therapeutics-inc-nasdaqnrix-given-average-rating-of-moderate-buy-by-brokerages-2026-07-15/", "source_name": "MarketBeat", "published_at": "2026-07-15T06:13:33", "published_display": "15 Jul 2026 06:13", "sentiment": "positive", "sentiment_pct": 63, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q3 EPS Estimates for Nurix Therapeutics Cut by HC Wainwright", "summary": "HC Wainwright has reduced its Q3 2026 EPS estimate for Nurix Therapeutics (NASDAQ:NRIX) to ($0.69) per share, down from ($0.68), while maintaining a \"Buy\" rating and a $34 price target. This follows Nurix's reported wider-than-expected Q2 loss of ($0.81) per share and revenue of ", "url": "https://www.marketbeat.com/instant-alerts/q3-eps-estimates-for-nurix-therapeutics-cut-by-hc-wainwright-2026-07-14/", "source_name": "MarketBeat", "published_at": "2026-07-14T11:14:20", "published_display": "14 Jul 2026 11:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sumitomo Mitsui Trust Group Inc. Sells 109,408 Shares of Nurix Therapeutics, Inc. $NRIX", "summary": "Sumitomo Mitsui Trust Group Inc. reduced its stake in Nurix Therapeutics (NRIX) by 8.5% in the first quarter, selling 109,408 shares. This comes as Nurix Therapeutics reported a weaker-than-expected quarterly loss and revenue miss. Despite insider selling, Wall Street analysts ma", "url": "https://www.marketbeat.com/instant-alerts/filing-sumitomo-mitsui-trust-group-inc-sells-109408-shares-of-nurix-therapeutics-inc-nrix-2026-07-14/", "source_name": "MarketBeat", "published_at": "2026-07-14T09:14:19", "published_display": "14 Jul 2026 09:14", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nurix stock price target raised to $34 by Mizuho on Roche deal", "summary": "Mizuho has increased its price target for Nurix Therapeutics Inc. (NASDAQ:NRIX) shares to $34 from $30, maintaining an Outperform rating, following the company's transformative deal with Roche for bexdeg. The adjustment incorporates the financial benefits and expanded opportuniti", "url": "https://m.investing.com/news/analyst-ratings/nurix-stock-price-target-raised-to-34-by-mizuho-on-roche-deal-93CH-4788228?ampMode=1", "source_name": "Investing.com", "published_at": "2026-07-13T20:14:19", "published_display": "13 Jul 2026 20:14", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mizuho Raises Price Target on Nurix Therapeutics to $34 From $30, Keeps Outperform Rating", "summary": "Mizuho has increased its price target for Nurix Therapeutics (NASDAQ: NRIX) to $34, up from the previous target of $30, while maintaining an Outperform rating on the stock. This adjustment suggests a positive outlook from the firm regarding Nurix Therapeutics' future performance ", "url": "https://www.moomoo.com/news/post/72856904/mizuho-raises-price-target-on-nurix-therapeutics-to-34-from?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-13T13:11:39", "published_display": "13 Jul 2026 13:11", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mizuho Forecasts Strong Price Appreciation for Nurix Therapeutics (NASDAQ:NRIX) Stock", "summary": "Mizuho has increased its price target for Nurix Therapeutics (NASDAQ:NRIX) from $30 to $34, maintaining an \"outperform\" rating, indicating a potential 47% upside. Despite this bullish outlook and a \"Moderate Buy\" consensus rating from analysts, Nurix recently reported wider-than-", "url": "https://www.marketbeat.com/instant-alerts/mizuho-forecasts-strong-price-appreciation-for-nurix-therapeutics-nasdaqnrix-stock-2026-07-13/", "source_name": "MarketBeat", "published_at": "2026-07-13T13:10:04", "published_display": "13 Jul 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "55,138 Shares in Nurix Therapeutics, Inc. $NRIX Acquired by Y Intercept Hong Kong Ltd", "summary": "Y Intercept Hong Kong Ltd has acquired 55,138 shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) during the first quarter, valued at approximately $855,000, representing about 0.05% ownership. While Wall Street analysts generally have a \"Moderate Buy\" rating with a target price of ", "url": "https://www.marketbeat.com/instant-alerts/filing-55138-shares-in-nurix-therapeutics-inc-nrix-acquired-by-y-intercept-hong-kong-ltd-2026-07-13/", "source_name": "MarketBeat", "published_at": "2026-07-13T11:10:03", "published_display": "13 Jul 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxPV1hqSFhQM3VfYlNsdldfeVQ1dEdNNzI3S1RTaFJNSThrOXlPSWpMTlR5WWVxNnNsTzhTVGVvTE94R18wa1A0OUdFczBlcTIzeUFBZUt6VVJJMjNqNks3dmRUSzB4cE40anpNekJwUXAwcTFEcVh4QVZCYURXY2w4b2thdk5KZ3ZJMnI1REJObXo5UDdISXVCU1Z2ZVZoVmJpbnEzaDVWVmpGQVNFZzRXYnp0SWRRWWZGSnZnWlJ4aEloNmJBNGRMVFRjb3ZRbmV3QXF5S0pvTV9xNnpaMWV1Z1ZtM3lPdV9RcEdURHlfZFphdjlicEJndW0ybHNBa205?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-13T03:32:00+00:00", "published_display": "13 Jul 2026 03:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Nurix Therapeutics (NASDAQ:NRIX) Raised to Sell at Wall Street Zen", "summary": "Wall Street Zen upgraded Nurix Therapeutics (NASDAQ:NRIX) from \"strong sell\" to \"sell,\" while most other analysts maintain a \"Moderate Buy\" rating with an average target price of $33.77. The company's stock fell 6.6% to $23.06 following the report, despite trading above its movin", "url": "https://www.marketbeat.com/instant-alerts/nurix-therapeutics-nasdaqnrix-raised-to-sell-at-wall-street-zen-2026-07-12/", "source_name": "MarketBeat", "published_at": "2026-07-12T17:39:42", "published_display": "12 Jul 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NURIX THERAPEUTICS, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $34 FROM $32", "summary": "H.C. Wainwright has increased its target price for NURIX THERAPEUTICS, INC. shares from $32 to $34. The news, reported by Reuters, indicates a positive re-evaluation of the company's financial outlook by the analyst firm. This adjustment suggests a higher expected value for the c", "url": "https://www.webull.com/news/15202429778715648", "source_name": "Webull", "published_at": "2026-07-12T08:11:39", "published_display": "12 Jul 2026 08:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nurix Therapeutics (NRIX) Stock Looks Pricey After Roche Deal And Weaker Quarter", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-11T22:25:57+00:00", "published_display": "11 Jul 2026 22:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Nurix Therapeutics, Inc. \u2013 NASDAQ:NRIX", "summary": "This article focuses on the enterprise value to EBITDA forward for Nurix Therapeutics, Inc. (NRIX) on the Nasdaq Stock Market. It provides a financial metric for the biotechnology company, indicating it was updated by humans and is available in English. The content is primarily a", "url": "https://www.tradingview.com/symbols/NASDAQ-NRIX/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-11T00:10:06", "published_display": "11 Jul 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Capital Initiates Nurix Therapeutics(NRIX.US) With Buy Rating, Announces Target Price $33", "summary": "RBC Capital has initiated coverage on Nurix Therapeutics (NRIX.US) with a Buy rating. The firm has set a price target of $33 for the company's stock. This indicates a positive outlook from RBC Capital regarding Nurix Therapeutics' future performance.", "url": "https://www.moomoo.com/news/post/72789338/rbc-capital-initiates-nurix-therapeutics-nrixus-with-buy-rating-announces", "source_name": "Moomoo", "published_at": "2026-07-10T18:09:20", "published_display": "10 Jul 2026 18:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nurix Therapeutics, Inc. Stock 12\u2011Month Price Target Raised to $32.25, Implies 31% Upside", "summary": "Nurix Therapeutics, Inc. (NRIX) has seen its average 12-month price target increase from $31.44 to $32.25, suggesting a potential 31% upside based on the July 9 closing price. This revised target is based on estimates from 16 analysts, with the consensus rating remaining a \"Buy.\"", "url": "https://www.tradingview.com/news/tradingview:52ac7bbcf526e:0-nurix-therapeutics-inc-stock-12-month-price-target-raised-to-32-25-implies-31-upside/", "source_name": "TradingView", "published_at": "2026-07-10T16:40:29", "published_display": "10 Jul 2026 16:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Russell Growth Index Additions Could Be A Game Changer For Nurix Therapeutics (NRIX)", "summary": "Nurix Therapeutics, Inc. (NRIX) was recently added to several Russell growth and small-cap indices, including the Russell 2000 Growth and Russell 2500 Growth. This inclusion is expected to increase the company's visibility among institutional investors and index funds. While this", "url": "https://www.sahmcapital.com/news/content/russell-growth-index-additions-could-be-a-game-changer-for-nurix-therapeutics-nrix-2026-07-09", "source_name": "Sahm", "published_at": "2026-07-10T16:09:20", "published_display": "10 Jul 2026 16:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nurix Therapeutics Releases Q2 2026 Financial Results", "summary": "Nurix Therapeutics reported a loss per share of $0.81 and revenue of $9.0M for Q2 2026, marking a significant revenue decline from the previous year. Despite widening losses due to investments in clinical development, Wall Street analysts maintain a positive outlook on the compan", "url": "https://news.alphastreet.com/nurix-therapeutics-releases-q2-2026-financial-results/", "source_name": "AlphaStreet", "published_at": "2026-07-10T15:40:29", "published_display": "10 Jul 2026 15:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nurix Therapeutics (NASDAQ:NRIX) Shares Down 8.6% After Earnings Miss", "summary": "Nurix Therapeutics (NASDAQ:NRIX) saw its shares drop 8.6% after reporting a significant earnings and revenue miss for the quarter, with EPS at -$0.81 against an expected -$0.72 and revenue of $9.04 million versus a $15.29 million forecast. Despite these weak results, the company ", "url": "https://www.marketbeat.com/instant-alerts/nurix-therapeutics-nasdaqnrix-shares-down-86-after-earnings-miss-2026-07-10/", "source_name": "MarketBeat", "published_at": "2026-07-10T14:40:29", "published_display": "10 Jul 2026 14:40", "sentiment": "negative", "sentiment_pct": 41, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nurix Therapeutics (NASDAQ:NRIX) Price Target Raised to $33.00 at Royal Bank Of Canada", "summary": "Royal Bank of Canada has increased its price target for Nurix Therapeutics (NASDAQ:NRIX) to $33.00, maintaining an \"outperform\" rating, which implies a potential upside of over 40%. This adjustment aligns with the overall constructive analyst sentiment, despite the company's rece", "url": "https://www.marketbeat.com/instant-alerts/nurix-therapeutics-nasdaqnrix-price-target-raised-to-3300-at-royal-bank-of-canada-2026-07-10/", "source_name": "MarketBeat", "published_at": "2026-07-10T13:40:29", "published_display": "10 Jul 2026 13:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nurix Therapeutics' Roche Deal Seen Driving Long-Term Upside, RBC Capital Markets Says", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/nurix-therapeutics-apos-roche-deal-123838779.html", "source_name": "MT Newswires", "published_at": "2026-07-10T12:38:38+00:00", "published_display": "10 Jul 2026 12:38", "sentiment": "positive", "sentiment_pct": 58, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update", "summary": "Nurix Therapeutics announced its second-quarter 2026 financial results, highlighted by a significant global collaboration agreement with Roche for its BTK degrader, bexobrutideg. This partnership includes a potential $2.3 billion in payments, with a $700 million upfront payment, ", "url": "https://ca.finance.yahoo.com/news/nurix-therapeutics-reports-second-quarter-200100127.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-07-10T07:41:13", "published_display": "10 Jul 2026 07:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nurix Therapeutics, Inc. (NRIX) reports Q2 loss, lags revenue estimates", "summary": "Nurix Therapeutics, Inc. (NRIX) reported a Q2 loss of $0.81 per share, missing the Zacks Consensus Estimate of a $0.73 loss, and revenues of $9.04 million, significantly below the $44.06 million from the prior year and missing consensus by 36.76%. Despite the disappointing earnin", "url": "https://www.fxstreet.com/news/nurix-therapeutics-inc-nrix-reports-q2-loss-lags-revenue-estimates-202607100706", "source_name": "FXStreet", "published_at": "2026-07-10T06:40:29", "published_display": "10 Jul 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nurix Therapeutics Q2 Loss Widens, Revenue Falls", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/nurix-therapeutics-q2-loss-widens-201515691.html", "source_name": "MT Newswires", "published_at": "2026-07-09T20:15:15+00:00", "published_display": "09 Jul 2026 20:15", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nurix Therapeutics (NASDAQ: NRIX) widens loss but secures $700M Roche bexobrutideg collaboration", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPbkpHMlRaVmpuLWhSVHRmTEZ4UGUxRlM3dnNVeTE1V29pX3Vwa251c1owcm91bG1YTVA1c29sRFhVNlZxRTlnNUZpQ294RDhCaGZZNWRvMVN6aHhCanVNaHhqSDRhQVBVT0lWajY4N2RMVFZiOFBGV04wNEo1MnlDb0N6QXU4YjR5bFZhNHJBc2ZlWGozcVlKdEtpOFNZNDBPNkFrM2lRTWZ4bVVuWTNIZHBPMS1sZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-09T20:12:47+00:00", "published_display": "09 Jul 2026 20:12", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] Nurix Therapeutics, Inc. Reports Material Event", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPRnpCaFFjN0FmRUFZMVFkeDBPZE52cDJQNFFlcDBzb284UHBPWDRoZzVZeUh4RzdSOFRqaGxsVWt0TFJLdDlJcDVEb1h3bHJhLUpvWmkzOVE3aDlMWlBEQnBucFdEVm9iVFNmbWNldF9EN1VtUk5DS1Q4NXFGWjF3VkxWeXBiN0VFeDhNeFFscERzNmZCb09MT1k5ZWEzc2hGSzNCSFA1ajU3bEZVQ2JWZg?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-09T20:10:20+00:00", "published_display": "09 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nurix Therapeutics Expects to Receive $700 M Upfront Payment From Roche in 3Q", "summary": "Nurix Therapeutics anticipates receiving a $700 million upfront payment from Roche in the third quarter. This payment is part of a previously announced collaboration between the two companies. The collaboration aims to develop novel targeted protein degradation drugs.", "url": "https://www.moomoo.com/news/post/72733856/nurix-therapeutics-expects-to-receive-700-m-upfront-payment-from?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-09T20:39:52", "published_display": "09 Jul 2026 20:39", "sentiment": "positive", "sentiment_pct": 91, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Nurix Therapeutics, Inc. \u2013 NASDAQ:NRIX", "summary": "This article focuses on the enterprise value to EBIT forward ratio for Nurix Therapeutics, Inc. (NASDAQ: NRIX). It appears to be a financial data page from TradingView, displaying key financial metrics for the company. The content primarily lists navigation and footer information", "url": "https://www.tradingview.com/symbols/NASDAQ-NRIX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T20:39:52", "published_display": "09 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nurix Therapeutics (NASDAQ:NRIX) Releases Quarterly Earnings Results", "summary": "Nurix Therapeutics (NASDAQ:NRIX) reported its quarterly earnings, missing analyst expectations for both EPS at ($0.81) versus ($0.73) and revenue at $9.04 million compared to $15.29 million. Despite the miss, the stock rose $0.38 to $24.69 on the day of the report, nearing its 12", "url": "https://www.marketbeat.com/instant-alerts/nurix-therapeutics-nasdaqnrix-releases-quarterly-earnings-results-2026-07-09/", "source_name": "MarketBeat", "published_at": "2026-07-09T20:39:52", "published_display": "09 Jul 2026 20:39", "sentiment": "negative", "sentiment_pct": 36, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nurix Therapeutics stock hits 52-week high at $24.93", "summary": "Nurix Therapeutics (NRIX) stock surged to a 52-week high of $24.93, reflecting a 94.63% increase over the past year and strong investor confidence. Despite projected sales decline by analysts and an \"overvalued\" rating by InvestingPro, the company's recent clinical trial results ", "url": "https://www.investing.com/news/company-news/nurix-therapeutics-stock-hits-52week-high-at-2493-93CH-4784374", "source_name": "Investing.com", "published_at": "2026-07-09T19:10:06", "published_display": "09 Jul 2026 19:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Flash (NRIX) Nurix Therapeutics, Inc. Reports Q2 Revenue $9.0M, vs. FactSet Est of $15.3M", "summary": "Nurix Therapeutics, Inc. (NRIX) reported its Q2 revenue at $9.0 million, significantly missing the FactSet estimate of $15.3 million. This earnings flash highlights that the company's Q2 loss widened and revenue fell, indicating a weaker financial performance than anticipated by ", "url": "https://www.marketscreener.com/news/earnings-flash-nrix-nurix-therapeutics-inc-reports-q2-revenue-9-0m-vs-factset-est-of-15-3m-ce7f5ededd88f320", "source_name": "marketscreener.com", "published_at": "2026-07-09T16:04:00", "published_display": "09 Jul 2026 16:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nurix Therapeutics stock hits 52-week high at $24.93 By Investing.com", "summary": "Nurix Therapeutics Inc. stock has reached a 52-week high of $24.93, reflecting a 94.63% increase over the past year. This surge follows positive clinical trial results for its BTK degrader, bexobrutideg, and a significant collaboration agreement with Roche, despite InvestingPro i", "url": "https://ng.investing.com/news/stock-market-news/nurix-therapeutics-stock-hits-52week-high-at-2493-93CH-2593459", "source_name": "Investing.com Nigeria", "published_at": "2026-07-09T15:06:00", "published_display": "09 Jul 2026 15:06", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nurix lands $700M Roche payment as CLL drug expands", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPQlpGcjBwMTR2aFlMTzVpOWxsOTlQN09uN0FxTXB1elNoemFsaEMyNjlEamdabVlsVGxCRy14U1FNTWNfR2dDOW9yaVI3ak0yOWRORmZTa1JZNHlkZklvUldXdzZTcnVYaUNjSWM0ZzdvODloSmwzcjZCbUx0REhQMkQ1Ny1fajlaLUNaZzNjV2FSRXVNWDkxNkdGd0lLWEZyby1RWnhYXy1yY3BoYWVrZExMekJDb2gyQkx0eTNDTWs?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-09T07:00:00+00:00", "published_display": "09 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Nurix Therapeutics, Inc. \u2013 NASDAQ:NRIX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQMDI2c1FOblhhdVBod18tNnFraGNiemFUZEJRY2stQjRzRVBjeDg2R2pVb2hQMk1qS0t3NFRNOUFjR25lMWw5a045S2xrd1FsNF9fQWV5TVBNdVhKSVBHdUYxWmdLbkxHX3l6Q3RaVkNsRUJQNkRBT1VkMHFJRUJBUjRkN1hXOEV4a1BvVlFQa0ZYZGRncWRqeUhHSlc1aURMWXc?oc=5", "source_name": "TradingView", "published_at": "2026-07-05T02:03:01+00:00", "published_display": "05 Jul 2026 02:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nurix (NRIX) Chief Legal Officer exercises options and sells 11,008 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNWmc5ZmplYlZxbFJmODU2VW1QaFZXMjc5bUZqRlRiRjdHTmtzUEtfcEtvUXNOcXlOZlRUcVhNWlloRjZBMW9VU2FhOFA3dFd6aWhIOHplWHd2bGdxbUQ4YUhVck9JZTdfMDUxbkp6Q0ZrcWRYOUEwUGxUdjFzM05tZmhBNGVkRVAySENSYnVrTktsdDZkLU55QWdLZm1fUkVGMWFibS1fdTRnS05iNGNUYTJvVl91QmM?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Christine Ring selling 11,008 NRIX shares (NASDAQ: NRIX) under Rule 144", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQRGhHZ1hfa3VPQmFzangzanJKWkpqQmdGRTZKNUx1VVk2WmRpTTdkM25sbVJBR28taXdjeU9sTVA0MGRRdzhGMTE1dmpiVE9WQnlxUk5iNU9KSGZyTThNcXNVUmVwa21PbV80NXhSb09RdjNtdk0yeHZycmZ4c0dfOTVCZ1IyTWl3bGlTRGpGcEZPT2VwcS1DTHdVVmdxYUlY?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Believe Nurix Therapeutics (NRIX) Could Rally 29.23%: Here's is How to Trade", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/wall-street-analysts-believe-nurix-135502714.html", "source_name": "Zacks", "published_at": "2026-07-01T13:55:02+00:00", "published_display": "01 Jul 2026 13:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Preview: Nurix Therapeutics, Inc. (NRIX) Q2 Earnings Expected to Decline", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQUU9SM2pIVDFoU1hWSTl5N29TWXgxU1BhZVRNbExhRVBiMllFRjVoV191WGprRS1NV3BSek4xdjhieHphcUp2Z1ByVkFKbjhqdmlhZlpPTHhfYkctTEFxdjE3cjFnSzRoSVYtRlZvQXZZTjBJSjVoZEd1ZlRwVXUyX08zNWlFSEw2TFA1ZjZ5amdibkJIaHRnNkNWdzFRWmk4TjlmNWdDdw?oc=5", "source_name": "Market source", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nurix Therapeutics, Inc. (NRIX) Price Target Raised to $33 on Roche Partnership Value", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/nurix-therapeutics-inc-nrix-price-132124008.html", "source_name": "Insider Monkey", "published_at": "2026-06-30T13:21:24+00:00", "published_display": "30 Jun 2026 13:21", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Nurix Therapeutics (NRIX) Overvalued As Its Roche Deal Lifts Hopes For Future Growth?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-27T07:00:00+00:00", "published_display": "27 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nurix Therapeutics (NRIX) Soars 16.4%: Is Further Upside Left in the Stock?", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/nurix-therapeutics-nrix-soars-16-144100417.html", "source_name": "Zacks", "published_at": "2026-06-26T14:41:00+00:00", "published_display": "26 Jun 2026 14:41", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Nurix Therapeutics Inc For: 25 June By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQNDZPdFVSQjAxT1ZDeWV2ZWc3TVNBVTZ5VFRRN1BzbndWZGM5ZU9iYzIwYi14TWZ2ckM4QUJmMURzYXgtcjktcExjZU5raGRydmVkSXE4dGlIR0lXWTJSM2RNM1pPN3NBbTBINDlzcVBtRjE2ZGM5aDQ0OU9CVlBKbGFlVGdWUnljanNnOFFJUTVqNWlIWUV4NGYyN1JlQjlHSlY0?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-06-25T22:51:25+00:00", "published_display": "25 Jun 2026 22:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRIX (NASDAQ) filing: 5,394 RSUs to be sold; 3,214 sold on 04/30/2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPbVplYlhOdmpnTnBsanhPZEFSUk56Q2RwaWRkaEd4MEFFazg0bVRVZkZNTWxOY3NmT2JGOGMzeElFS1lESnRQMFZId09UOHlpY3Y3WDJua1k3dDUxOEJhcm4tVm1ZOXREay1YSG54eXZGM2ZzcHpwa2dFTGsxblNEYUdiVVY4VXVKUHNkNUYzczJpNU5yM1NFb01kd1QtODFZ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nurix (NRIX) Climbs to 52-Week High \u2014 This Deal May Hold the Answer", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOa29FZVdpMU11OU92MUpfSVlZclB5N0ZGZllvR3RtOTFUNmIxSnVwTjlvRWNVQnNLNkR4NHMtdWtUN0FIQXhtN0s1cl9KZnEwZUcwY0dBaW1BWmdHX002ZU5ONGdjSF9VM3BFd1ZFSHBoYzZMYzZHYkVXOVNsMmxPZmZTemNrQ1FkVF9ScVBZeUdjTVJw?oc=5", "source_name": "Market source", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nurix Therapeutics (NRIX) Stock Looks Expensive Even With A $31 Analyst Target", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPb0I2T2ZudVpSSndZR0Uxa0hkZzhZR2xSbWl6M0cxMXROaVpPWk12QlBsNmdIZ1ZNb2NBX3JZNVpnalFicUZja29FTUY5VndaS25aald4d3gybkE1QVNtay0xQjdFZC1rRkRNdUpBeE1PbnFobWM2TEdHd0ZBRVFCNkxVcEtFY1lHUzY4dzI4azFabUVkb1VSb1h0LTRENm9fQkE?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nurix Therapeutics: 'Strong Buy' Due To Roche Deal And Bexobrutideg Expansions", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNbG1QYlBFSmRfMjNIZW9oc3IyWHVOZ1ppYU5vTmI1Zm9keXU2TXF5aTdmbmVsRVhxMEhMeWVoS1RFUDNxLTJYMzNCeUo1aDZQX0xtLXpZaWw4dXFoMjduQWRsdmIwSW0tRDNQd2c1OFJWT2tpZVdzTmtjWWpuMmxHRk11eTFyWGNaN21xc0Y0alpnUVJ1S2I4SUpmWHZKZGtfZUJvZ1ZVY1hPSzBqUlZqS3JwTjJveTQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Strength Seen in Nurix Therapeutics (NRIX): Can Its 6.8% Jump Turn into More Strength?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOcGpEeVhQTFJmZjBlZnoyV0s4bmN6RmVLOXYzQTFFZHJSQjBPNG5pa2xhREVHdVhYMXlkRldBR3lvanZNeHNUZXJ0bmZSV0Y5Nkt3Y2h0SkwxSWNGN1Zyd3F6c3FRVU1KNGxJSkJ1NkJWbkhLcGZpMGt6elBLajFmLUNSQkhLZ2lqNUFZZERPWm1jbDZWdHgwV0tuNm5fYjBOMU1KaQ?oc=5", "source_name": "Market source", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRIX Stock Surges Nearly 70% Premarket Today \u2013 Roche And Nurix\u2019s Blood Cancer Drug Collaboration Can Tap A $41B Market", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwJBVV95cUxQUHVqSF9TMndkbWxqSXBSSEZHVmlkMFdFb01NLW5McGd2NlJKNEZaSTNERjZNWmlVLUxRVWQ0STJCTG9OLWZObmtUN1ZlOXJ1TEhEbi1ZTUJzV2Mwc2dEaTU5OVgwZEVodkZGZDBIckwyWU1kZlZ3dlY4VlhuMGMzSllpd0pXMk0yUHR3cjFHdFhMaTVMTkFGc1FReEZweVhjMTFsZTEwWlJ4NERCRm1VNGg5c0cyX2JIQ0RyYWtoRV9hSFFCZndSc2hTVmV3cjFTVHh2TWpTLUlXZXllV2Rlbm56N0NjbEJPZ2R5azRVQ25EMTdJbUxwWHFMZTB4YXBMOEE4Uk9sWEl4cVk?oc=5", "source_name": "Stocktwits", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nurix surges 43% on up to $3B cancer drug deal with Roche (RHHBY:OTCMKTS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNcU1NbXpNMDdYX0w3eUhXZmVSX2gxdDNXRUdKenB4VC1nMHZpd3ptU1NCS3NvX1ktLVZSTzUwTTlUeUlMdUdaaE85SXREbkozdXFDMi1JbDVMcVphbWhlN0RVZlIyelNpTERhRzZ5ZEIzX2YweHJNNk5qVlpnakdMem15eWdGdmxXRk5DYUhYSmp4eUx0RTJodg?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roche Enters $2.3 Billion Global Collaboration with Nurix Therapeutics to Co-Develop and Co-Commercialize Bexobrutideg", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOS0tqWHdJcmM2d2huTmJmX1ViWVVLV3d1eE1fV2NlNEhvNDU1UHN6Z2FVRmNuV28ydkJZcDBiZjBhMVB6MzNjOGQybTJta0V4bzE2QndVZzRsbldYVDJXdDJCSm1IUDFNYXl4N2t5MkhZV1FHMTN6dE9pVm9iRV9TRmZGaGpPa1NCMEFLYmRXa183ams1LTNPN3RlNnc2N1ZXWVdUVTR4Z093bmgzZFdFZHA2Mm5LUDBpV3B5Y3VkeU91NXdOZlE?oc=5", "source_name": "Pharmaceutical Executive", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nurix (NASDAQ: NRIX) lands $700M Roche bexobrutideg pact with up to $2.3B", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPeU5RSVZmaUc1STRMS0tDb0lNRkpIMGdHazVlT1BSZ00xcnRWakVGN08wTDJRZmZ3SVRkU29kb1F4Y2txS25wZ1NKa2ZqWXZ6dnV4UVR3bDFQa054Wlhidnl2bmZPZm5WendXOFRxcHIzM0p5Q01nWWozdm5OQ0JBdzVmcEZDblZjMzRKdmY5SEJpWGxKYVY2UEtYa2NkS0NoSm5mUXVqTDJBM2ctZE9lMg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biggest stock movers Monday: NRIX, INTC, and more (NASDAQ:NRIX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMic0FVX3lxTE9QTC1oWndGcW1BeF80NEZHcF9kZGxPOXhmQm5WOTBZczA5ckhURkhzd05aak0yUE5pUUN2d1ZUTmVXczAzMWpBVTl4dXExeXpBX3BCY0w4TWZUb2t6SkNNUXlBTE83WkRRdXpDZkFuR1N1QU0?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Deep Track files 6.17% ownership in Nurix Therapeutics (NRIX) \u2014 6.35M shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxPbW9yTWxjNG94YUtGX1pwQTB2Y2dqaHpwOWhVdDFPTzZMVkgtaXBud0haMm9CbkhFVm9NNlR2bDJ3QjRLeHQ3MmpQb2hTWl9yWmdTWGtxcE81MFh1ZXhWQ3N0OEh3dkt6Z3MyZnV4VnNWYm9vbWJ5bWM1UzBES1hfTDN1NlBsSlJSVGJ1TjNUN05hamFnSjJ5VFU3NHo2S1A1ZFlueTZ6bF9jVFJRM2VYeTFXZEdZazNJN003Z012dUV6cGg1eHQ0ZG9wQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "In preclinical brain metastasis model, Nurix drug lifted lifespan 142%", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPckltNHA3cUVEZkllM1Y3Y2tZbTVwT2tITlpzMXhSaVVUV1V3ejI4WlVLNmppUGhRWThWUFVjYWR3ODZwamg0VWM1Z01BM1VfTTluV0wzMm8xaEZvdE1RVEg0eUJCWVdWX2lMSkl5YjFZMjhxb1ctUkRXZE5ZZlQ4bFFTeUxXMkhhNjVVTkR4bWt2VnJFSTcyWXk1VGQ4bTR5VHFGeDRFTHNGZzNUQ2FsVHMxRVliOFBX?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "by_tier": {"direct": [{"title": "Nurix Therapeutics, Inc. Stock 12\u2011Month Price Target Raised to $32.87, Implies 42% Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxNZ3VFYVYxMnpUTnZrX08xTlozaGU3cmw1MzZ5cm1mYzlhSjNPbGN0dWZwU2daYmIyLUVGUWRRR25Qemt0d1hLSGpMd1J5a0J4V1VJTUhSQTJHUlQxdl9hM0hNMDBjT2lhN0gyR2hfRVEzbUVHTmhRZWlpLXJEWno0NkFuMmJjb29TQi16UGhZQ3R3U1lXcEVwVXR2YVpJVzB2LUFSb3dQNUI2SGI3Zm9NQ2diR1Izek0xYzZ0NUVYUFo0U3dQODdlbDVIOW0yUllaZDFsTmtUWjQybFdQd1lN?oc=5", "source_name": "TradingView", "published_at": "2026-07-17T04:20:00+00:00", "published_display": "17 Jul 2026 04:20", "sentiment": "positive", "sentiment_pct": 80, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Average Rating of \"Moderate Buy\" by Brokerages", "summary": "Nurix Therapeutics, Inc. (NASDAQ:NRIX) has received an average rating of \"Moderate Buy\" from fourteen brokerages, with an average 12-month price target of $34.08. Several analysts have recently raised their price targets, despite the company missing its latest quarterly earnings ", "url": "https://www.marketbeat.com/instant-alerts/nurix-therapeutics-inc-nasdaqnrix-given-average-rating-of-moderate-buy-by-brokerages-2026-07-15/", "source_name": "MarketBeat", "published_at": "2026-07-15T06:13:33", "published_display": "15 Jul 2026 06:13", "sentiment": "positive", "sentiment_pct": 63, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q3 EPS Estimates for Nurix Therapeutics Cut by HC Wainwright", "summary": "HC Wainwright has reduced its Q3 2026 EPS estimate for Nurix Therapeutics (NASDAQ:NRIX) to ($0.69) per share, down from ($0.68), while maintaining a \"Buy\" rating and a $34 price target. This follows Nurix's reported wider-than-expected Q2 loss of ($0.81) per share and revenue of ", "url": "https://www.marketbeat.com/instant-alerts/q3-eps-estimates-for-nurix-therapeutics-cut-by-hc-wainwright-2026-07-14/", "source_name": "MarketBeat", "published_at": "2026-07-14T11:14:20", "published_display": "14 Jul 2026 11:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sumitomo Mitsui Trust Group Inc. Sells 109,408 Shares of Nurix Therapeutics, Inc. $NRIX", "summary": "Sumitomo Mitsui Trust Group Inc. reduced its stake in Nurix Therapeutics (NRIX) by 8.5% in the first quarter, selling 109,408 shares. This comes as Nurix Therapeutics reported a weaker-than-expected quarterly loss and revenue miss. Despite insider selling, Wall Street analysts ma", "url": "https://www.marketbeat.com/instant-alerts/filing-sumitomo-mitsui-trust-group-inc-sells-109408-shares-of-nurix-therapeutics-inc-nrix-2026-07-14/", "source_name": "MarketBeat", "published_at": "2026-07-14T09:14:19", "published_display": "14 Jul 2026 09:14", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nurix stock price target raised to $34 by Mizuho on Roche deal", "summary": "Mizuho has increased its price target for Nurix Therapeutics Inc. (NASDAQ:NRIX) shares to $34 from $30, maintaining an Outperform rating, following the company's transformative deal with Roche for bexdeg. The adjustment incorporates the financial benefits and expanded opportuniti", "url": "https://m.investing.com/news/analyst-ratings/nurix-stock-price-target-raised-to-34-by-mizuho-on-roche-deal-93CH-4788228?ampMode=1", "source_name": "Investing.com", "published_at": "2026-07-13T20:14:19", "published_display": "13 Jul 2026 20:14", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mizuho Raises Price Target on Nurix Therapeutics to $34 From $30, Keeps Outperform Rating", "summary": "Mizuho has increased its price target for Nurix Therapeutics (NASDAQ: NRIX) to $34, up from the previous target of $30, while maintaining an Outperform rating on the stock. This adjustment suggests a positive outlook from the firm regarding Nurix Therapeutics' future performance ", "url": "https://www.moomoo.com/news/post/72856904/mizuho-raises-price-target-on-nurix-therapeutics-to-34-from?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-13T13:11:39", "published_display": "13 Jul 2026 13:11", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mizuho Forecasts Strong Price Appreciation for Nurix Therapeutics (NASDAQ:NRIX) Stock", "summary": "Mizuho has increased its price target for Nurix Therapeutics (NASDAQ:NRIX) from $30 to $34, maintaining an \"outperform\" rating, indicating a potential 47% upside. Despite this bullish outlook and a \"Moderate Buy\" consensus rating from analysts, Nurix recently reported wider-than-", "url": "https://www.marketbeat.com/instant-alerts/mizuho-forecasts-strong-price-appreciation-for-nurix-therapeutics-nasdaqnrix-stock-2026-07-13/", "source_name": "MarketBeat", "published_at": "2026-07-13T13:10:04", "published_display": "13 Jul 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "55,138 Shares in Nurix Therapeutics, Inc. $NRIX Acquired by Y Intercept Hong Kong Ltd", "summary": "Y Intercept Hong Kong Ltd has acquired 55,138 shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) during the first quarter, valued at approximately $855,000, representing about 0.05% ownership. While Wall Street analysts generally have a \"Moderate Buy\" rating with a target price of ", "url": "https://www.marketbeat.com/instant-alerts/filing-55138-shares-in-nurix-therapeutics-inc-nrix-acquired-by-y-intercept-hong-kong-ltd-2026-07-13/", "source_name": "MarketBeat", "published_at": "2026-07-13T11:10:03", "published_display": "13 Jul 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nurix Therapeutics (NASDAQ:NRIX) Raised to Sell at Wall Street Zen", "summary": "Wall Street Zen upgraded Nurix Therapeutics (NASDAQ:NRIX) from \"strong sell\" to \"sell,\" while most other analysts maintain a \"Moderate Buy\" rating with an average target price of $33.77. The company's stock fell 6.6% to $23.06 following the report, despite trading above its movin", "url": "https://www.marketbeat.com/instant-alerts/nurix-therapeutics-nasdaqnrix-raised-to-sell-at-wall-street-zen-2026-07-12/", "source_name": "MarketBeat", "published_at": "2026-07-12T17:39:42", "published_display": "12 Jul 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NURIX THERAPEUTICS, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $34 FROM $32", "summary": "H.C. Wainwright has increased its target price for NURIX THERAPEUTICS, INC. shares from $32 to $34. The news, reported by Reuters, indicates a positive re-evaluation of the company's financial outlook by the analyst firm. This adjustment suggests a higher expected value for the c", "url": "https://www.webull.com/news/15202429778715648", "source_name": "Webull", "published_at": "2026-07-12T08:11:39", "published_display": "12 Jul 2026 08:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nurix Therapeutics (NRIX) Stock Looks Pricey After Roche Deal And Weaker Quarter", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-11T22:25:57+00:00", "published_display": "11 Jul 2026 22:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Nurix Therapeutics, Inc. \u2013 NASDAQ:NRIX", "summary": "This article focuses on the enterprise value to EBITDA forward for Nurix Therapeutics, Inc. (NRIX) on the Nasdaq Stock Market. It provides a financial metric for the biotechnology company, indicating it was updated by humans and is available in English. The content is primarily a", "url": "https://www.tradingview.com/symbols/NASDAQ-NRIX/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-11T00:10:06", "published_display": "11 Jul 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Capital Initiates Nurix Therapeutics(NRIX.US) With Buy Rating, Announces Target Price $33", "summary": "RBC Capital has initiated coverage on Nurix Therapeutics (NRIX.US) with a Buy rating. The firm has set a price target of $33 for the company's stock. This indicates a positive outlook from RBC Capital regarding Nurix Therapeutics' future performance.", "url": "https://www.moomoo.com/news/post/72789338/rbc-capital-initiates-nurix-therapeutics-nrixus-with-buy-rating-announces", "source_name": "Moomoo", "published_at": "2026-07-10T18:09:20", "published_display": "10 Jul 2026 18:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nurix Therapeutics, Inc. Stock 12\u2011Month Price Target Raised to $32.25, Implies 31% Upside", "summary": "Nurix Therapeutics, Inc. (NRIX) has seen its average 12-month price target increase from $31.44 to $32.25, suggesting a potential 31% upside based on the July 9 closing price. This revised target is based on estimates from 16 analysts, with the consensus rating remaining a \"Buy.\"", "url": "https://www.tradingview.com/news/tradingview:52ac7bbcf526e:0-nurix-therapeutics-inc-stock-12-month-price-target-raised-to-32-25-implies-31-upside/", "source_name": "TradingView", "published_at": "2026-07-10T16:40:29", "published_display": "10 Jul 2026 16:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Russell Growth Index Additions Could Be A Game Changer For Nurix Therapeutics (NRIX)", "summary": "Nurix Therapeutics, Inc. (NRIX) was recently added to several Russell growth and small-cap indices, including the Russell 2000 Growth and Russell 2500 Growth. This inclusion is expected to increase the company's visibility among institutional investors and index funds. While this", "url": "https://www.sahmcapital.com/news/content/russell-growth-index-additions-could-be-a-game-changer-for-nurix-therapeutics-nrix-2026-07-09", "source_name": "Sahm", "published_at": "2026-07-10T16:09:20", "published_display": "10 Jul 2026 16:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nurix Therapeutics Releases Q2 2026 Financial Results", "summary": "Nurix Therapeutics reported a loss per share of $0.81 and revenue of $9.0M for Q2 2026, marking a significant revenue decline from the previous year. Despite widening losses due to investments in clinical development, Wall Street analysts maintain a positive outlook on the compan", "url": "https://news.alphastreet.com/nurix-therapeutics-releases-q2-2026-financial-results/", "source_name": "AlphaStreet", "published_at": "2026-07-10T15:40:29", "published_display": "10 Jul 2026 15:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nurix Therapeutics (NASDAQ:NRIX) Shares Down 8.6% After Earnings Miss", "summary": "Nurix Therapeutics (NASDAQ:NRIX) saw its shares drop 8.6% after reporting a significant earnings and revenue miss for the quarter, with EPS at -$0.81 against an expected -$0.72 and revenue of $9.04 million versus a $15.29 million forecast. Despite these weak results, the company ", "url": "https://www.marketbeat.com/instant-alerts/nurix-therapeutics-nasdaqnrix-shares-down-86-after-earnings-miss-2026-07-10/", "source_name": "MarketBeat", "published_at": "2026-07-10T14:40:29", "published_display": "10 Jul 2026 14:40", "sentiment": "negative", "sentiment_pct": 41, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nurix Therapeutics (NASDAQ:NRIX) Price Target Raised to $33.00 at Royal Bank Of Canada", "summary": "Royal Bank of Canada has increased its price target for Nurix Therapeutics (NASDAQ:NRIX) to $33.00, maintaining an \"outperform\" rating, which implies a potential upside of over 40%. This adjustment aligns with the overall constructive analyst sentiment, despite the company's rece", "url": "https://www.marketbeat.com/instant-alerts/nurix-therapeutics-nasdaqnrix-price-target-raised-to-3300-at-royal-bank-of-canada-2026-07-10/", "source_name": "MarketBeat", "published_at": "2026-07-10T13:40:29", "published_display": "10 Jul 2026 13:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nurix Therapeutics' Roche Deal Seen Driving Long-Term Upside, RBC Capital Markets Says", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/nurix-therapeutics-apos-roche-deal-123838779.html", "source_name": "MT Newswires", "published_at": "2026-07-10T12:38:38+00:00", "published_display": "10 Jul 2026 12:38", "sentiment": "positive", "sentiment_pct": 58, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update", "summary": "Nurix Therapeutics announced its second-quarter 2026 financial results, highlighted by a significant global collaboration agreement with Roche for its BTK degrader, bexobrutideg. This partnership includes a potential $2.3 billion in payments, with a $700 million upfront payment, ", "url": "https://ca.finance.yahoo.com/news/nurix-therapeutics-reports-second-quarter-200100127.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-07-10T07:41:13", "published_display": "10 Jul 2026 07:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nurix Therapeutics, Inc. (NRIX) reports Q2 loss, lags revenue estimates", "summary": "Nurix Therapeutics, Inc. (NRIX) reported a Q2 loss of $0.81 per share, missing the Zacks Consensus Estimate of a $0.73 loss, and revenues of $9.04 million, significantly below the $44.06 million from the prior year and missing consensus by 36.76%. Despite the disappointing earnin", "url": "https://www.fxstreet.com/news/nurix-therapeutics-inc-nrix-reports-q2-loss-lags-revenue-estimates-202607100706", "source_name": "FXStreet", "published_at": "2026-07-10T06:40:29", "published_display": "10 Jul 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nurix Therapeutics Q2 Loss Widens, Revenue Falls", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/nurix-therapeutics-q2-loss-widens-201515691.html", "source_name": "MT Newswires", "published_at": "2026-07-09T20:15:15+00:00", "published_display": "09 Jul 2026 20:15", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nurix Therapeutics (NASDAQ: NRIX) widens loss but secures $700M Roche bexobrutideg collaboration", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPbkpHMlRaVmpuLWhSVHRmTEZ4UGUxRlM3dnNVeTE1V29pX3Vwa251c1owcm91bG1YTVA1c29sRFhVNlZxRTlnNUZpQ294RDhCaGZZNWRvMVN6aHhCanVNaHhqSDRhQVBVT0lWajY4N2RMVFZiOFBGV04wNEo1MnlDb0N6QXU4YjR5bFZhNHJBc2ZlWGozcVlKdEtpOFNZNDBPNkFrM2lRTWZ4bVVuWTNIZHBPMS1sZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-09T20:12:47+00:00", "published_display": "09 Jul 2026 20:12", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] Nurix Therapeutics, Inc. Reports Material Event", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPRnpCaFFjN0FmRUFZMVFkeDBPZE52cDJQNFFlcDBzb284UHBPWDRoZzVZeUh4RzdSOFRqaGxsVWt0TFJLdDlJcDVEb1h3bHJhLUpvWmkzOVE3aDlMWlBEQnBucFdEVm9iVFNmbWNldF9EN1VtUk5DS1Q4NXFGWjF3VkxWeXBiN0VFeDhNeFFscERzNmZCb09MT1k5ZWEzc2hGSzNCSFA1ajU3bEZVQ2JWZg?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-09T20:10:20+00:00", "published_display": "09 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nurix Therapeutics Expects to Receive $700 M Upfront Payment From Roche in 3Q", "summary": "Nurix Therapeutics anticipates receiving a $700 million upfront payment from Roche in the third quarter. This payment is part of a previously announced collaboration between the two companies. The collaboration aims to develop novel targeted protein degradation drugs.", "url": "https://www.moomoo.com/news/post/72733856/nurix-therapeutics-expects-to-receive-700-m-upfront-payment-from?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-09T20:39:52", "published_display": "09 Jul 2026 20:39", "sentiment": "positive", "sentiment_pct": 91, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Nurix Therapeutics, Inc. \u2013 NASDAQ:NRIX", "summary": "This article focuses on the enterprise value to EBIT forward ratio for Nurix Therapeutics, Inc. (NASDAQ: NRIX). It appears to be a financial data page from TradingView, displaying key financial metrics for the company. The content primarily lists navigation and footer information", "url": "https://www.tradingview.com/symbols/NASDAQ-NRIX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T20:39:52", "published_display": "09 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nurix Therapeutics (NASDAQ:NRIX) Releases Quarterly Earnings Results", "summary": "Nurix Therapeutics (NASDAQ:NRIX) reported its quarterly earnings, missing analyst expectations for both EPS at ($0.81) versus ($0.73) and revenue at $9.04 million compared to $15.29 million. Despite the miss, the stock rose $0.38 to $24.69 on the day of the report, nearing its 12", "url": "https://www.marketbeat.com/instant-alerts/nurix-therapeutics-nasdaqnrix-releases-quarterly-earnings-results-2026-07-09/", "source_name": "MarketBeat", "published_at": "2026-07-09T20:39:52", "published_display": "09 Jul 2026 20:39", "sentiment": "negative", "sentiment_pct": 36, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nurix Therapeutics stock hits 52-week high at $24.93", "summary": "Nurix Therapeutics (NRIX) stock surged to a 52-week high of $24.93, reflecting a 94.63% increase over the past year and strong investor confidence. Despite projected sales decline by analysts and an \"overvalued\" rating by InvestingPro, the company's recent clinical trial results ", "url": "https://www.investing.com/news/company-news/nurix-therapeutics-stock-hits-52week-high-at-2493-93CH-4784374", "source_name": "Investing.com", "published_at": "2026-07-09T19:10:06", "published_display": "09 Jul 2026 19:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Flash (NRIX) Nurix Therapeutics, Inc. Reports Q2 Revenue $9.0M, vs. FactSet Est of $15.3M", "summary": "Nurix Therapeutics, Inc. (NRIX) reported its Q2 revenue at $9.0 million, significantly missing the FactSet estimate of $15.3 million. This earnings flash highlights that the company's Q2 loss widened and revenue fell, indicating a weaker financial performance than anticipated by ", "url": "https://www.marketscreener.com/news/earnings-flash-nrix-nurix-therapeutics-inc-reports-q2-revenue-9-0m-vs-factset-est-of-15-3m-ce7f5ededd88f320", "source_name": "marketscreener.com", "published_at": "2026-07-09T16:04:00", "published_display": "09 Jul 2026 16:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nurix Therapeutics stock hits 52-week high at $24.93 By Investing.com", "summary": "Nurix Therapeutics Inc. stock has reached a 52-week high of $24.93, reflecting a 94.63% increase over the past year. This surge follows positive clinical trial results for its BTK degrader, bexobrutideg, and a significant collaboration agreement with Roche, despite InvestingPro i", "url": "https://ng.investing.com/news/stock-market-news/nurix-therapeutics-stock-hits-52week-high-at-2493-93CH-2593459", "source_name": "Investing.com Nigeria", "published_at": "2026-07-09T15:06:00", "published_display": "09 Jul 2026 15:06", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nurix lands $700M Roche payment as CLL drug expands", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPQlpGcjBwMTR2aFlMTzVpOWxsOTlQN09uN0FxTXB1elNoemFsaEMyNjlEamdabVlsVGxCRy14U1FNTWNfR2dDOW9yaVI3ak0yOWRORmZTa1JZNHlkZklvUldXdzZTcnVYaUNjSWM0ZzdvODloSmwzcjZCbUx0REhQMkQ1Ny1fajlaLUNaZzNjV2FSRXVNWDkxNkdGd0lLWEZyby1RWnhYXy1yY3BoYWVrZExMekJDb2gyQkx0eTNDTWs?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-09T07:00:00+00:00", "published_display": "09 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Nurix Therapeutics, Inc. \u2013 NASDAQ:NRIX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQMDI2c1FOblhhdVBod18tNnFraGNiemFUZEJRY2stQjRzRVBjeDg2R2pVb2hQMk1qS0t3NFRNOUFjR25lMWw5a045S2xrd1FsNF9fQWV5TVBNdVhKSVBHdUYxWmdLbkxHX3l6Q3RaVkNsRUJQNkRBT1VkMHFJRUJBUjRkN1hXOEV4a1BvVlFQa0ZYZGRncWRqeUhHSlc1aURMWXc?oc=5", "source_name": "TradingView", "published_at": "2026-07-05T02:03:01+00:00", "published_display": "05 Jul 2026 02:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nurix (NRIX) Chief Legal Officer exercises options and sells 11,008 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNWmc5ZmplYlZxbFJmODU2VW1QaFZXMjc5bUZqRlRiRjdHTmtzUEtfcEtvUXNOcXlOZlRUcVhNWlloRjZBMW9VU2FhOFA3dFd6aWhIOHplWHd2bGdxbUQ4YUhVck9JZTdfMDUxbkp6Q0ZrcWRYOUEwUGxUdjFzM05tZmhBNGVkRVAySENSYnVrTktsdDZkLU55QWdLZm1fUkVGMWFibS1fdTRnS05iNGNUYTJvVl91QmM?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Christine Ring selling 11,008 NRIX shares (NASDAQ: NRIX) under Rule 144", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQRGhHZ1hfa3VPQmFzangzanJKWkpqQmdGRTZKNUx1VVk2WmRpTTdkM25sbVJBR28taXdjeU9sTVA0MGRRdzhGMTE1dmpiVE9WQnlxUk5iNU9KSGZyTThNcXNVUmVwa21PbV80NXhSb09RdjNtdk0yeHZycmZ4c0dfOTVCZ1IyTWl3bGlTRGpGcEZPT2VwcS1DTHdVVmdxYUlY?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Believe Nurix Therapeutics (NRIX) Could Rally 29.23%: Here's is How to Trade", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/wall-street-analysts-believe-nurix-135502714.html", "source_name": "Zacks", "published_at": "2026-07-01T13:55:02+00:00", "published_display": "01 Jul 2026 13:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Preview: Nurix Therapeutics, Inc. (NRIX) Q2 Earnings Expected to Decline", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQUU9SM2pIVDFoU1hWSTl5N29TWXgxU1BhZVRNbExhRVBiMllFRjVoV191WGprRS1NV3BSek4xdjhieHphcUp2Z1ByVkFKbjhqdmlhZlpPTHhfYkctTEFxdjE3cjFnSzRoSVYtRlZvQXZZTjBJSjVoZEd1ZlRwVXUyX08zNWlFSEw2TFA1ZjZ5amdibkJIaHRnNkNWdzFRWmk4TjlmNWdDdw?oc=5", "source_name": "Market source", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nurix Therapeutics, Inc. (NRIX) Price Target Raised to $33 on Roche Partnership Value", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/nurix-therapeutics-inc-nrix-price-132124008.html", "source_name": "Insider Monkey", "published_at": "2026-06-30T13:21:24+00:00", "published_display": "30 Jun 2026 13:21", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Nurix Therapeutics (NRIX) Overvalued As Its Roche Deal Lifts Hopes For Future Growth?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-27T07:00:00+00:00", "published_display": "27 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nurix Therapeutics (NRIX) Soars 16.4%: Is Further Upside Left in the Stock?", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/nurix-therapeutics-nrix-soars-16-144100417.html", "source_name": "Zacks", "published_at": "2026-06-26T14:41:00+00:00", "published_display": "26 Jun 2026 14:41", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Nurix Therapeutics Inc For: 25 June By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQNDZPdFVSQjAxT1ZDeWV2ZWc3TVNBVTZ5VFRRN1BzbndWZGM5ZU9iYzIwYi14TWZ2ckM4QUJmMURzYXgtcjktcExjZU5raGRydmVkSXE4dGlIR0lXWTJSM2RNM1pPN3NBbTBINDlzcVBtRjE2ZGM5aDQ0OU9CVlBKbGFlVGdWUnljanNnOFFJUTVqNWlIWUV4NGYyN1JlQjlHSlY0?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-06-25T22:51:25+00:00", "published_display": "25 Jun 2026 22:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRIX (NASDAQ) filing: 5,394 RSUs to be sold; 3,214 sold on 04/30/2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPbVplYlhOdmpnTnBsanhPZEFSUk56Q2RwaWRkaEd4MEFFazg0bVRVZkZNTWxOY3NmT2JGOGMzeElFS1lESnRQMFZId09UOHlpY3Y3WDJua1k3dDUxOEJhcm4tVm1ZOXREay1YSG54eXZGM2ZzcHpwa2dFTGsxblNEYUdiVVY4VXVKUHNkNUYzczJpNU5yM1NFb01kd1QtODFZ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nurix (NRIX) Climbs to 52-Week High \u2014 This Deal May Hold the Answer", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOa29FZVdpMU11OU92MUpfSVlZclB5N0ZGZllvR3RtOTFUNmIxSnVwTjlvRWNVQnNLNkR4NHMtdWtUN0FIQXhtN0s1cl9KZnEwZUcwY0dBaW1BWmdHX002ZU5ONGdjSF9VM3BFd1ZFSHBoYzZMYzZHYkVXOVNsMmxPZmZTemNrQ1FkVF9ScVBZeUdjTVJw?oc=5", "source_name": "Market source", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nurix Therapeutics (NRIX) Stock Looks Expensive Even With A $31 Analyst Target", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPb0I2T2ZudVpSSndZR0Uxa0hkZzhZR2xSbWl6M0cxMXROaVpPWk12QlBsNmdIZ1ZNb2NBX3JZNVpnalFicUZja29FTUY5VndaS25aald4d3gybkE1QVNtay0xQjdFZC1rRkRNdUpBeE1PbnFobWM2TEdHd0ZBRVFCNkxVcEtFY1lHUzY4dzI4azFabUVkb1VSb1h0LTRENm9fQkE?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nurix Therapeutics: 'Strong Buy' Due To Roche Deal And Bexobrutideg Expansions", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNbG1QYlBFSmRfMjNIZW9oc3IyWHVOZ1ppYU5vTmI1Zm9keXU2TXF5aTdmbmVsRVhxMEhMeWVoS1RFUDNxLTJYMzNCeUo1aDZQX0xtLXpZaWw4dXFoMjduQWRsdmIwSW0tRDNQd2c1OFJWT2tpZVdzTmtjWWpuMmxHRk11eTFyWGNaN21xc0Y0alpnUVJ1S2I4SUpmWHZKZGtfZUJvZ1ZVY1hPSzBqUlZqS3JwTjJveTQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Strength Seen in Nurix Therapeutics (NRIX): Can Its 6.8% Jump Turn into More Strength?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOcGpEeVhQTFJmZjBlZnoyV0s4bmN6RmVLOXYzQTFFZHJSQjBPNG5pa2xhREVHdVhYMXlkRldBR3lvanZNeHNUZXJ0bmZSV0Y5Nkt3Y2h0SkwxSWNGN1Zyd3F6c3FRVU1KNGxJSkJ1NkJWbkhLcGZpMGt6elBLajFmLUNSQkhLZ2lqNUFZZERPWm1jbDZWdHgwV0tuNm5fYjBOMU1KaQ?oc=5", "source_name": "Market source", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRIX Stock Surges Nearly 70% Premarket Today \u2013 Roche And Nurix\u2019s Blood Cancer Drug Collaboration Can Tap A $41B Market", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwJBVV95cUxQUHVqSF9TMndkbWxqSXBSSEZHVmlkMFdFb01NLW5McGd2NlJKNEZaSTNERjZNWmlVLUxRVWQ0STJCTG9OLWZObmtUN1ZlOXJ1TEhEbi1ZTUJzV2Mwc2dEaTU5OVgwZEVodkZGZDBIckwyWU1kZlZ3dlY4VlhuMGMzSllpd0pXMk0yUHR3cjFHdFhMaTVMTkFGc1FReEZweVhjMTFsZTEwWlJ4NERCRm1VNGg5c0cyX2JIQ0RyYWtoRV9hSFFCZndSc2hTVmV3cjFTVHh2TWpTLUlXZXllV2Rlbm56N0NjbEJPZ2R5azRVQ25EMTdJbUxwWHFMZTB4YXBMOEE4Uk9sWEl4cVk?oc=5", "source_name": "Stocktwits", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nurix surges 43% on up to $3B cancer drug deal with Roche (RHHBY:OTCMKTS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNcU1NbXpNMDdYX0w3eUhXZmVSX2gxdDNXRUdKenB4VC1nMHZpd3ptU1NCS3NvX1ktLVZSTzUwTTlUeUlMdUdaaE85SXREbkozdXFDMi1JbDVMcVphbWhlN0RVZlIyelNpTERhRzZ5ZEIzX2YweHJNNk5qVlpnakdMem15eWdGdmxXRk5DYUhYSmp4eUx0RTJodg?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roche Enters $2.3 Billion Global Collaboration with Nurix Therapeutics to Co-Develop and Co-Commercialize Bexobrutideg", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOS0tqWHdJcmM2d2huTmJmX1ViWVVLV3d1eE1fV2NlNEhvNDU1UHN6Z2FVRmNuV28ydkJZcDBiZjBhMVB6MzNjOGQybTJta0V4bzE2QndVZzRsbldYVDJXdDJCSm1IUDFNYXl4N2t5MkhZV1FHMTN6dE9pVm9iRV9TRmZGaGpPa1NCMEFLYmRXa183ams1LTNPN3RlNnc2N1ZXWVdUVTR4Z093bmgzZFdFZHA2Mm5LUDBpV3B5Y3VkeU91NXdOZlE?oc=5", "source_name": "Pharmaceutical Executive", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nurix (NASDAQ: NRIX) lands $700M Roche bexobrutideg pact with up to $2.3B", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPeU5RSVZmaUc1STRMS0tDb0lNRkpIMGdHazVlT1BSZ00xcnRWakVGN08wTDJRZmZ3SVRkU29kb1F4Y2txS25wZ1NKa2ZqWXZ6dnV4UVR3bDFQa054Wlhidnl2bmZPZm5WendXOFRxcHIzM0p5Q01nWWozdm5OQ0JBdzVmcEZDblZjMzRKdmY5SEJpWGxKYVY2UEtYa2NkS0NoSm5mUXVqTDJBM2ctZE9lMg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biggest stock movers Monday: NRIX, INTC, and more (NASDAQ:NRIX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMic0FVX3lxTE9QTC1oWndGcW1BeF80NEZHcF9kZGxPOXhmQm5WOTBZczA5ckhURkhzd05aak0yUE5pUUN2d1ZUTmVXczAzMWpBVTl4dXExeXpBX3BCY0w4TWZUb2t6SkNNUXlBTE83WkRRdXpDZkFuR1N1QU0?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Deep Track files 6.17% ownership in Nurix Therapeutics (NRIX) \u2014 6.35M shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxPbW9yTWxjNG94YUtGX1pwQTB2Y2dqaHpwOWhVdDFPTzZMVkgtaXBud0haMm9CbkhFVm9NNlR2bDJ3QjRLeHQ3MmpQb2hTWl9yWmdTWGtxcE81MFh1ZXhWQ3N0OEh3dkt6Z3MyZnV4VnNWYm9vbWJ5bWM1UzBES1hfTDN1NlBsSlJSVGJ1TjNUN05hamFnSjJ5VFU3NHo2S1A1ZFlueTZ6bF9jVFJRM2VYeTFXZEdZazNJN003Z012dUV6cGg1eHQ0ZG9wQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "In preclinical brain metastasis model, Nurix drug lifted lifespan 142%", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPckltNHA3cUVEZkllM1Y3Y2tZbTVwT2tITlpzMXhSaVVUV1V3ejI4WlVLNmppUGhRWThWUFVjYWR3ODZwamg0VWM1Z01BM1VfTTluV0wzMm8xaEZvdE1RVEg0eUJCWVdWX2lMSkl5YjFZMjhxb1ctUkRXZE5ZZlQ4bFFTeUxXMkhhNjVVTkR4bWt2VnJFSTcyWXk1VGQ4bTR5VHFGeDRFTHNGZzNUQ2FsVHMxRVliOFBX?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxPV1hqSFhQM3VfYlNsdldfeVQ1dEdNNzI3S1RTaFJNSThrOXlPSWpMTlR5WWVxNnNsTzhTVGVvTE94R18wa1A0OUdFczBlcTIzeUFBZUt6VVJJMjNqNks3dmRUSzB4cE40anpNekJwUXAwcTFEcVh4QVZCYURXY2w4b2thdk5KZ3ZJMnI1REJObXo5UDdISXVCU1Z2ZVZoVmJpbnEzaDVWVmpGQVNFZzRXYnp0SWRRWWZGSnZnWlJ4aEloNmJBNGRMVFRjb3ZRbmV3QXF5S0pvTV9xNnpaMWV1Z1ZtM3lPdV9RcEdURHlfZFphdjlicEJndW0ybHNBa205?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-13T03:32:00+00:00", "published_display": "13 Jul 2026 03:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 99, "total_relevant": 63, "sentiment_summary": {"positive": 23, "negative": 9, "neutral": 31, "score": 56, "total": 63, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 73, "events": [{"event": "general", "label": "Market update", "weight": 12.6, "count": 21}, {"event": "earnings", "label": "Earnings", "weight": 11.96, "count": 24}, {"event": "analyst", "label": "Analyst action", "weight": 7.15, "count": 13}, {"event": "deals", "label": "Deals and strategy", "weight": 3.45, "count": 5}], "positive_events": 23, "negative_events": 9}, "market_context": {"has_market_context": true, "latest_close": 23.06, "latest_week": "2026-07-10", "one_week_move": -3.8, "four_week_move": 36.0, "twelve_week_move": 31.7, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.081672, "market_dynamics_buy_signal": false, "relative_strength": 32.853287, "fair_value_gap": 56.9, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 54.5078, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-3.8% over one week, +36.0% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 63, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 9}, {"label": "MarketBeat", "count": 9}, {"label": "Stock Titan", "count": 9}, {"label": "TradingView", "count": 5}, {"label": "simplywall.st", "count": 4}, {"label": "Moomoo", "count": 3}, {"label": "Seeking Alpha", "count": 3}, {"label": "Investing.com", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 54}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 24}, {"label": "Market update", "count": 21}, {"label": "Analyst action", "count": 13}, {"label": "Deals and strategy", "count": 5}]}, "insights": [{"label": "Weighted tone", "value": "56/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "73/100 classification confidence."}, {"label": "Company focus", "value": "54", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "5", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-3.8% over one week, +36.0% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Nurix Therapeutics, Inc. Stock 12\u2011Month Price Target Raised to $32.87, Implies 42% Upside"}], "updated_at": "2026-07-17T11:45:24.754506+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}